FindTrial
Sign In

Guselkumab 100 mg

DRUG4 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutica N.V., Belgium, Janssen-Cilag Ltd.

Conditions

Arthritis, PsoriaticPsoriasis

Phase 3

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
CompletedNCT02207231
Janssen Research & Development, LLCPsoriasis
Start: 2014-11-26End: 2020-06-17Updated: 2021-07-23
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
CompletedNCT02207244
Janssen Research & Development, LLCPsoriasis
Start: 2014-11-03End: 2020-07-01Updated: 2021-07-22
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
CompletedNCT03796858
Janssen Pharmaceutica N.V., BelgiumArthritis, Psoriatic
Start: 2019-03-22End: 2020-11-11Updated: 2025-02-03
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
CompletedNCT03998683
Janssen-Cilag Ltd.Psoriasis
Start: 2019-09-03End: 2021-11-30Updated: 2022-01-03

Related Papers

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study.
2026-01-23
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials.
2025-12-15
Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
2025-10-28
Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison.
2025-08-01
Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial.
2024-08-171 citations
Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy.
2024-06-053 citations
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
2024-03-155 citations
Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison
Rheumatology and Therapy2024-03-154 citations
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
2023-10-3131 citations
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
American Journal of Clinical Dermatology2023-10-074 citations
Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
2023-09-261 citations
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
2023-09-157 citations
Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
2023-09-153 citations
Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study.
2023-08-167 citations
AB1082 EARLY CLINICAL RESPONSE AS A PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS AND TNFI-IR RECEIVING GUSELKUMAB (COSMOS)
2023-05-301 citations
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis
The Journal of Rheumatology2023-01-1515 citations
A Phase IIIb, Multicentre, Interventional, Randomised, Placebo‐Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G‐PLUS)
Dermatologic Therapy2023-01-014 citations
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
2021-11-2473 citations
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
2020-12-0122 citations
Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study.
2020-04-168 citations

4 more papers not shown